ClinicalTrials.gg
RecruitingNCT07421297Updated Apr 7, 2026

A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia

A Phase 3 interventional study of SYH2053 injection and SYH2053 injection placebo in Non-familial Hypercholesterolemia and Mixed Hyperlipidemia, sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
760
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 24 studies in Hyperlipoproteinemia Type II with a site in China — 13 open to participants now, 14 under way, 8 of them phase 3. Hyperlipoproteinemia Type II · China.

Planned enrollment
4th of 22
760 · median 142
Started
2026
with 5 others
Phase 3
13 of 24
6 open now
Primary completion
2027-12
later than 8 of 13 live
Registered
19th of 24
by date
Lead sponsor
5 of 24
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

Among the 24 studies in Hyperlipoproteinemia Type II with a site in China, this one is the 4th largest by planned enrollment of the 22 interventional ones that give a count, is one of 6 that started in 2026, is one of 13 in phase 3, reaches primary completion later than 8 of the 13 other live ones, and was the 19th registered.

Hyperlipoproteinemia Type II

249 studies on the registry are indexed under Hyperlipoproteinemia Type II; 56 are open to participants now.

Browse Hyperlipoproteinemia Type II studies →

Open to participants now

13 of the 24 studies in Hyperlipoproteinemia Type II with a site in China are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 36 Hyperlipoproteinemia Type II studies recruiting now, 17 (47%) set no upper age limit and 15 (42%) stop at 75 or younger; 17 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Hyperlipoproteinemia Type II with a site in China, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of SYH2053 monotherapy in patients with primary hypercholesterolemia (non-familial) or mixed dyslipidemia .

This trial plans to enroll 760 Participants.

03

Conditions studied

  • Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 、Age ≥18 years (inclusive);
  2. 、Fasting serum low-density lipoprotein cholesterol (LDL-C) levels failing to meet the target criteria at screening and prior to randomization (based on local laboratory results). Any one of the following conditions satisfies the criterion(according to the 2023 Chinese Guidelines for Lipid Management):① Low risk: LDL-C ≥130 mg/dL(3.4 mmol/L)and LDL-C\<188 mg/dL(4.9 mmol/L); ②Moderate risk: LDL-C ≥ 100 mg/dL (2.6 mmol/L) and LDL-C\<188 mg/dL(4.9 mmol/L); 3、At screening (based on local laboratory results), Fasting serum Triglyceride (TG)\<500 mg/dL(5.6 mmol/L) 4、Participants are able to establish good communication with the investigator and complete the trial in accordance with the protocol.

Exclusion criteria

Exclusion Criteria:

  1. Prior diagnosis of familial hypercholesterolemia; or a history of the following diseases: Cushing's syndrome, nephrotic syndrome, myeloma, glycogen storage disease, systemic lupus erythematosus, acute intermittent porphyria, cirrhosis, severe biliary obstruction, or other diseases known to significantly cause dyslipidemia;
  2. A documented history of established atherosclerotic cardiovascular disease (ASCVD), defined as a history of: acute coronary syndrome (myocardial infarction or unstable angina), chronic coronary syndrome, or prior coronary revascularization (e.g., PCI or CABG); ischemic stroke or (TIA); or significant peripheral artery disease (PAD). PAD includes conditions such as chronic limb-threatening ischemia, acute limb ischemia, or atherosclerotic disease in other major arteries (e.g., carotid, vertebral, subclavian, renal, or mesenteric arteries);
  3. Treatment with short-acting lipid-lowering therapies (e.g., statins, fibrates, bempedoic acid, ezetimibe, bile acid sequestrants, niacin, omega-3 fatty acids) or any preparation of unknown composition with lipid-lowering intent (including over-the-counter, traditional, or herbal medicines) within 90 days prior to screening; or treatment with PCSK9 monoclonal antibodies or oral PCSK9 inhibitors within the past 180 days before screening or treatment with inclisiran or any other RNA-based lipid-lowering therapy (e.g., siRNA, antisense oligonucleotide) within the past 2 years before screening;
  4. History of within 5 years (excluding treated basal cell carcinoma of the skin), or presence of a suspected malignancy currently being evaluated by the investigator;
  5. At screening, Systolic blood pressure (SBP) > 160 mmHg or diastolic blood pressure (DBP) > 100 mmHg(either in untreated patients or in those on stable medical therapy) ;
  6. History of heart failure with Class III-IV within 180days before screening or prior to Randomization;
  7. At screening, \< 30 mL/min/1.73 m²(as calculated by the CKD-EPI equation);
  8. At screening, Creatine Kinase (CK) > 3 × ;
  9. At screening, (ALT) or aspartate aminotransferase (AST) > 3 × ULN or Total (TBIL), > 1.5 × ULN (unless attributable to Gilbert's syndrome);
  10. At screening, prolonged /QTcF interval at Screening Period or prior to Randomization (QTcF > 450 ms for males, > 470 ms for females)
  11. Positive result for any one of surface antigen (HBsAg), virus (HCV) antibody, syphilis antibody, or (HIV) antibody;
  12. At screening, > 8.0% at screening Period or prior to Randomization; or Type 1 diabetes , gestational diabetes ;
  13. History of drug abuse within 5 years, including the recurrent use of dependence-producing drugs or substances unrelated to medical purposes in large quantities, including addictive and habituating drugs that cause physical and psychological dependence;
  14. History of alcohol abuse within 1 year (defined as consuming more than 14 units of alcohol per week [1 unit = 360 mL of beer with 5% alcohol content, or 45 mL of spirits with 40% alcohol content, or 150 mL of wine with 12% alcohol content]);
  15. Participation in any other clinical trial involving the administration of an drug within 3 months prior to Screening or within 5 half-lives of the other investigational drug (whichever is longer), or plans to participate in any other clinical trial during the study period;
  16. Any condition that, in the Investigator's opinion, may interfere with the conduct of the study, including but not limited to: a. presence of any disease within 6 months prior to Screening through the study period that may interfere with study results; b. any other reason that would prevent the subject from completing the study or that makes them inappropriate for inclusion;
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
760 participants (estimated)

Study arms

  • Experimental
    SYH2053 injection

    Administer the medication in accordance with the requirements of the clinical trial protocol

    Drug: SYH2053 injection

  • Placebo comparator
    SYH2053 injection placebo

    Administer the medication in accordance with the requirements of the clinical trial protocol

    Other: SYH2053 injection placebo

Interventions

  • Participants receive SYH2053 injection by subcutaneous administration.

  • OtherSYH2053 injection placebo

    Participants receive SYH2053 injection placebo by subcutaneous administration.

06

What researchers measure

Primary outcomes

  1. Percentage change in LDL-C relative to baseline

    Time frame: Day 330

Secondary outcomes

  1. The value of change in LDL-C relative to baseline

    Time frame: Day 330

  2. Time adjusted percent change in LDL-C levels from baseline between Day 90 and Day 360 levels

    Time frame: Day 90-360

  3. Incidence and severity of adverse events (AE), serious adverse events (SAE), etc. Description:

    Time frame: Days 1-360

  4. Number of ADA and Nab

    Time frame: Day 30-360

07

Study locations

1 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2027, 22 months after the start.

Of 29 industry-sponsored phase 3 interventional studies under Hyperlipoproteinemia Type II, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 34. This study's planned 22 months is close to that.

Counting every sponsor, half of 33 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 12, 2026
First posted
Feb 19, 2026
StartActual
Feb 28, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jan 31, 2028
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07421297
Responsible party
Sponsor
First posted
Feb 19, 2026
Start date
Feb 28, 2026
Primary completion
Dec 31, 2027 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Apr 7, 2026

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
0311-69085587

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SYH2053

Start the discussion